Advanced Therapies For End-Stage Heart Failure

Management of the advanced heart failure patient can be complex. Therapies include cardiac transplantation and mechanical circulatory support, as well inotropic agents for the short-term. Despite a growing armamentarium of resources, the clinician must carefully weigh the risks and benefits of each therapy to develop an optimal treatment strategy. While cardiac transplantation remains the only true “cure” for end-stage disease, this resource is limited and the demand continues to far outpace the supply. For patients who are transplant-ineligible or likely to succumb to their illness prior to transplant, ventricular assist device therapy has now become a viable option for improving morbidity and mortality. Particularly for the non-operative pa-tient, intravenous inotropes can be utilized for symptom control. Regardless of the treatments considered, care of the heart failure patient requires thoughtful dialogue, multidisciplinary collaboration, and individualized care. While survival is important, most patients covet quality of life above all outcomes. An often overlooked component is the patient’s control over the dying process. It is vital that clinicians make goals-of-care discussions a priority when seeing patients with advanced heart failure. The use of palliative care consultation is well-validated and facilitates these difficult conversations to ensure that all patient needs are ultimately met.

[1]  D. Burkhoff,et al.  Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy , 2003, Circulation.

[2]  E. Adler,et al.  End-of-Life Options for Patients with Advanced Heart Failure , 2010, Current heart failure reports.

[3]  S. Hunt,et al.  A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. , 1993, The New England journal of medicine.

[4]  K. Peterson,et al.  Exercise hemodynamics during long-term implantation of a left ventricular assist device in patients awaiting heart transplantation. , 1993, Journal of the American College of Cardiology.

[5]  C. O'connor,et al.  Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. , 2008, JAMA.

[6]  L. Allen,et al.  Palliative care and hospice in advanced heart failure. , 2011, Progress in cardiovascular diseases.

[7]  H. Ross,et al.  How aware of advanced care directives are heart failure patients, and are they using them? , 2011, The Canadian journal of cardiology.

[8]  J R Wilson,et al.  Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure , 1991, Circulation.

[9]  M. Hammond,et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.

[10]  D. Mancini,et al.  Prognostic impact of the addition of peak oxygen consumption to the Seattle Heart Failure Model in a transplant referral population. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  L. Stevenson,et al.  Left ventricular assist devices: bridges to transplantation, recovery, and destination for whom? , 2003, Circulation.

[12]  A. Abernethy,et al.  Preferences of people with advanced heart failure-a structured narrative literature review to inform decision making in the palliative care setting. , 2012, American heart journal.

[13]  Clive Lewis,et al.  The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  M. Schnitzler,et al.  Chronic inotropic therapy in end-stage heart failure. , 2006, American heart journal.

[15]  A. Koshal,et al.  Troponin T and I are not reliable markers of cardiac transplant rejection. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  James Yee,et al.  Gene-expression profiling for rejection surveillance after cardiac transplantation. , 2010, The New England journal of medicine.

[17]  M. Lishner,et al.  Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: A randomized, double‐blind, placebo‐controlled study , 1998, Clinical pharmacology and therapeutics.

[18]  A. Caplan,et al.  24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. , 1993, Journal of the American College of Cardiology.

[19]  Pranav Loyalka,et al.  Use of an Intrapericardial, Continuous-Flow, Centrifugal Pump in Patients Awaiting Heart Transplantation , 2012, Circulation.

[20]  P. Macdonald,et al.  Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. , 1997, American heart journal.

[21]  A. Israni,et al.  OPTN/SRTR 2011 Annual Data Report: Heart , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  Robert L Kormos,et al.  Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[24]  J. H. Gibbon,et al.  Application of a mechanical heart and lung apparatus to cardiac surgery. , 1954, Minnesota medicine.

[25]  A. Caplan,et al.  Task force 3: Recipient guidelines/prioritization , 1993 .

[26]  Stuart Russell,et al.  Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  R. Starling,et al.  Brain natriuretic peptide levels do not correlate with acute cellular rejection in De Novo orthotopic heart transplant recipients. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  N. Freemantle,et al.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysis , 2002, European journal of heart failure.

[29]  D. N. Helman,et al.  History of mechanical circulatory support. , 2000, Progress in cardiovascular diseases.

[30]  Harlan M Krumholz,et al.  Detection of heart transplant rejection in adults by echocardiographic diastolic indices: a systematic review of the literature. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[31]  P. Ganz,et al.  Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial , 2002, The Lancet.

[32]  M. Shishehbor,et al.  Prognosis on Chronic Dobutamine or Milrinone Infusions for Stage D Heart Failure , 2009, Circulation. Heart failure.

[33]  Josef Stehlik,et al.  The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[34]  J. Kirkpatrick,et al.  Ethical challenges in advanced heart failure , 2013, Current opinion in supportive and palliative care.

[35]  R. Starling,et al.  International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[36]  N. Uriel,et al.  Preoperative Assessment of High-Risk Candidates to Predict Survival After Heart Transplantation , 2013, Circulation. Heart failure.

[37]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[38]  A. Maggioni,et al.  Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. , 1999, American heart journal.

[39]  E. Wolfel,et al.  Drug therapy in the heart transplant recipient: Part III: common medical problems. , 2005, Circulation.

[40]  T. Klingler,et al.  Noninvasive Discrimination of Rejection in Cardiac Allograft Recipients Using Gene Expression Profiling , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[41]  M. Lauer,et al.  Peak Oxygen Consumption as a Predictor of Death in Patients With Heart Failure Receiving β-Blockers , 2005, Circulation.

[42]  D. Meier,et al.  Palliative Care in the Treatment of Advanced Heart Failure , 2009, Circulation.

[43]  A. Delaney,et al.  Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials , 2012, Intensive Care Medicine.

[44]  N. Uriel,et al.  Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. , 2010, Journal of the American College of Cardiology.

[45]  M. Allen,et al.  Effects of gender on peak oxygen consumption and the timing of cardiac transplantation. , 2005, Journal of the American College of Cardiology.

[46]  G. Miller,et al.  Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. , 2005, Circulation.

[47]  D. Mancini,et al.  Pretransplant evaluationDevelopment and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation , 1996 .

[48]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[49]  Silviu Itescu,et al.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[50]  C. Lavie,et al.  The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. , 2000, Journal of the American College of Cardiology.

[51]  O H Frazier,et al.  Use of a continuous-flow device in patients awaiting heart transplantation. , 2007, The New England journal of medicine.

[52]  A. López-Candales,et al.  Need for hospice and palliative care services in patients with end‐stage heart failure treated with intermittent infusion of inotropes , 2004, Clinical cardiology.

[53]  L. Miller Listing criteria for cardiac transplantation: results of an American Society of Transplant Physicians-National Institutes of Health conference. , 1998, Transplantation.

[54]  M E DeBakey,et al.  Left ventricular bypass pump for cardiac assistance. Clinical experience. , 1971, The American journal of cardiology.